Simmons Comprehensive Cancer Center - Administration - Directors Office - Administration

Research output

Research output per year 1982 2019 2020 2021 2022 2023 2024

• 490 Article
• 53 Review article
• 31 Comment/debate
• 13 Editorial
• 23 More
  • 8 Letter
  • 5 Chapter
  • 5 Conference contribution
  • 5 Short survey

Research output per year

Research output per year

Search results

• 2023

  Opportunities to Advance Equity Through Informed Consent Discussions

  Umaretiya, P. J. & Johnston, E. E., 2023, (Accepted/In press) In: JAMA Network Open. p. E2346814

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access
• 2021

  Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821–1830] (Annals of Oncology (2019) 30(11) (1821–1830), (S0923753420325904))

  Jhaveri, K. L., Wang, X. V., Makker, V., Luoh, S. W., Mitchell, E. P., Zwiebel, J. A., Sharon, E., Gray, R. J., Li, S., McShane, L. M., Rubinstein, L. V., Patton, D., Williams, P. M., Hamilton, S. R., Conley, B. A., Arteaga, C. L., Harris, L. N., O'Dwyer, P. J., Chen, A. P. & Flaherty, K. T., Aug 2021, In: Annals of Oncology. 32, 8, p. 1068 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Ado-Trastuzumab Emtansine 100%
  • Esophagogastric Junction 78%
  • Biotechnology 70%
  • Disclosure 67%
  • Adenocarcinoma 47%

• Erratum: Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors (Cell Reports (2021) 35(1), (S2211124721002588), (10.1016/j.celrep.2021.108944))

  Uzhachenko, R. V., Bharti, V., Ouyang, Z., Blevins, A., Mont, S., Saleh, N., Lawrence, H. A., Shen, C., Chen, S. C., Ayers, G. D., DeNardo, D. G., Arteaga, C., Richmond, A. & Vilgelm, A. E., Jun 22 2021, In: Cell Reports. 35, 12, 109271.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Puma 100%
  • Remuneration 91%
  • Organized Financing 75%
  • Manuscripts 73%
  • Biotechnology 73%
  6 Scopus citations
• 2020

  Erratum: Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers (Cancer Cell (2020) 37(2) (183–199.e5), (S1535610819305835), (10.1016/j.ccell.2019.12.013))

  Sudhan, D. R., Guerrero-Zotano, A., Won, H., Ericsson, P. G., Servetto, A., Huerta-Rosario, M., Ye, D., Lee, K. M., Formisano, L., Guo, Y., Liu, Q., Kinch, L. N., Brewer, M. R., Dugger, T., Koch, J., Wick, M. J., Cutler, R. E., Lalani, A. S., Bryce, R., Auerbach, A., & 2 othersHanker, A. B. & Arteaga, C. L., Feb 10 2020, In: Cancer Cell. 37, 2, p. 258-259 2 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide 100%
  • Lapatinib 80%
  • Mechanistic Target of Rapamycin Complex 1 72%
  • Protein-Tyrosine Kinases 52%
  • Neoplasms 18%
  9 Scopus citations
• 2019

  Conceptual model for accrual to cancer clinical trials

  Craddock Lee, S. J., Murphy, C. C., Geiger, A. M., Gerber, D. E., Cox, J. V., Nair, R. & Skinner, C. S., Aug 10 2019, In: Journal of Clinical Oncology. 37, 23, p. 1993-1996 4 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access
  21 Scopus citations

• Correction: Neratinib: Inching up on the cure rate of HER2 ^þ breast cancer? (Clin Cancer Res) (2019) 24 (3483–3485) Doi: 10.1158/1078-0432.CCR-18-1114)

  Unni, N., Sudhan, D. R. & Arteaga, C. L., Feb 15 2019, In: Clinical Cancer Research. 25, 4, p. 1430 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  • N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide 100%
  • Disclosure 63%
  • Emotions 45%
  • Breast Neoplasms 36%
  • Neoplasms 18%

• Correction: Pik3ca c2 domain deletions hyperactivate phosphoinositide 3-kinase (pi3k), generate oncogene dependence, and are exquisitely sensitive to pi3ka inhibitors(Clin Cancer Res (2018) 24 (1426–35)DOI: 10.1158/1078-0432.CCR-17-2141)

  Croessmann, S., Sheehan, J. H., Lee, K. M., Sliwoski, G., He, J., Nagy, R., Riddle, D., Mayer, I. A., Balko, J. M., Lanman, R., Miller, V. A., Cantley, L. C., Meiler, J. & Arteaga, C. L., Feb 15 2019, In: Clinical Cancer Research. 25, 4, p. 1432 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  • C2 Domains 100%
  • Disclosure 75%
  • Phosphatidylinositol 3-Kinase 69%
  • Oncogenes 64%
  • Emotions 53%

• Correction: Treatment of triple-negative breast cancer with TORC1/2 inhibitors sustains a drug-resistant and Notch-dependent cancer stem cell population (Cancer Research (2016) 76 (440–452) DOI: 10.1158/0008-5472.CAN-15-1640-T)

  Bhola, N. E., Jansen, V. M., Koch, J. P., Li, H., Formisano, L., Williams, J. A., Grandis, J. R. & Arteaga, C. L., Feb 15 2019, In: Cancer research. 79, 4, p. 875 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Mechanistic Target of Rapamycin Complex 1 100%
  • Triple Negative Breast Neoplasms 95%
  • Disclosure 87%
  • Neoplastic Stem Cells 84%
  • Emotions 62%
  1 Scopus citations

• Correction: RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors(Clin Cancer Res. (2016)22:6 (1499-509) DOI: 10.1158/1078-0432.CCR-15-1125)

  Loi, S., Dushyanthen, S., Beavis, P. A., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. L., Giltnane, J. M., Estrada, M. V., Sanchez, V., Sanders, M. E., Cook, R. S., Pilkinton, M. A., Mallal, S. A., Wang, K., Miller, V. A., Stephens, P. J., Yelensky, R., Doimi, F. D., & 5 othersGomez, H., Ryzhov, S. V., Darcy, P. K., Arteaga, C. L. & Balko, J. M., Feb 15 2019, In: Clinical Cancer Research. 25, 4, 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Tumor-Infiltrating Lymphocytes 100%
  • Triple Negative Breast Neoplasms 95%
  • Disclosure 86%
  • Mitogen-Activated Protein Kinase Kinases 85%
  • Emotions 62%
  12 Scopus citations

• Correction: Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer (Cancer Research (2015) 75 (405–414) DOI: 10.1158/0008-5472.CAN-14-2475)

  Bhola, N. E., Jansen, V. M., Bafna, S., Giltnane, J. M., Balko, J. M., Estrada, M. V., Meszoely, I., Mayer, I., Abramson, V., Ye, F., Sanders, M., Dugger, T. C., Allen, E. V. & Arteaga, C. L., Feb 15 2019, In: Cancer research. 79, 4, p. 876 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  • Disclosure 100%
  • Emotions 71%
  • Hormones 63%
  • Breast Neoplasms 57%
  • Neoplasms 29%
  2 Scopus citations

• Correction: Extracellular matrix/integrin signaling promotes resistance to combined inhibition of HER2 and PI3K in HER2 ^þ breast cancer (Cancer Research (2017) 77 (3280–3292) DOI: 10.1158/0008-5472.CAN-16-2808)

  Hanker, A. B., Estrada, M. V., Bianchini, G., Moore, P. D., Zhao, J., Cheng, F., Koch, J. P., Gianni, L., Tyson, D. R., Sánchez, V., Rexer, B. N., Sanders, M. E., Zhao, Z., Stricker, T. P. & Arteaga, C. L., Feb 15 2019, In: Cancer research. 79, 4, p. 873 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Disclosure 100%
  • Phosphatidylinositol 3-Kinases 89%
  • Integrins 85%
  • Extracellular Matrix 76%
  • Psychological Inhibition 74%
  1 Scopus citations

• Correction: ¹⁸ F-fluoroestradiol PET/CT measurement of estrogen receptor suppression during a phase I trial of the novel estrogen receptor-targeted therapeutic GDC-0810: Using an imaging biomarker to guide drug dosage in subsequent trials(Clin Cancer Res. (2017) 3:12 (3053-3060) DOI: 10.1158/1078-0432.CCR-16-219)

  Wang, Y., Ayres, K. L., Goldman, D. A., Dickler, M. N., Bardia, A., Mayer, I. A., Winer, E., Fredrickson, J., Arteaga, C. L., Baselga, J., Manning, H. C., Mahmood, U. & Ulaner, G. A., Feb 15 2019, In: Clinical Cancer Research. 25, 4, p. 1435 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • 3-(4-(2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid 100%
  • Disclosure 49%
  • Estrogen Receptors 41%
  • Emotions 35%
  • Biomarkers 29%
  1 Scopus citations

• Correction: HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2(Clin Cancer Res. (2017) 23:15 (4323-4334) DOI: 10.1158/1078-0432.CCR-16-2287)

  Hanker, A. B., Garrett, J. T., Valeria Estrada, M., Moore, P. D., Ericsson, P. G., Koch, J. P., Langley, E., Singh, S., Kim, P. S., Frampton, G. M., Sanford, E., Owens, P., Becker, J., Groseclose, M. R., Castellino, S., Joensuu, H., Huober, J., Brase, J. C., Majjaj, S., Brohee, S., & 6 othersVenet, D., Brown, D., Baselga, J., Piccart, M., Sotiriou, C. & Arteaga, C. L., Feb 15 2019, In: Clinical Cancer Research. 25, 4, p. 1434 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Disclosure 100%
  • Emotions 71%
  • Breast Neoplasms 57%
  • Neoplasms 29%
  • Therapeutics 14%

• Correction: ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors (Clinical Cancer Research (2018) 24 (2517–29) DOI: 10.1158/1078-0432.CCR-17-2904)

  Guerrero-Zotano, A. L., Stricker, T. P., Formisano, L., Hutchinson, K. E., Stover, D. G., Lee, K. M., Schwarz, L. J., Giltnane, J. M., Estrada, M. V., Jansen, V. M., Servetto, A., Gavila, J. J., Perez-Fidalgo, A., Lluch, A., Llombart-Cussac, A., Bayar, M. A., Michiels, S., Andre, F., Arnedos, M., Guillem, V., & 2 othersRuiz-Simon, A. & Arteaga, C. L., Feb 15 2019, In: Clinical Cancer Research. 25, 4, p. 1431 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Letrozole 100%
  • Disclosure 79%
  • Emotions 57%
  • Breast Neoplasms 46%
  • Neoplasms 23%
  1 Scopus citations

• Correction: Association of FGFR1 with ERA maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER ^þ breast cancer (Clinical Cancer Research (2019)23 (6138–6150) Doi:10.1158/1078-0432.CCR-17-1232)

  Formisano, L., Stauffer, K. M., Young, C. D., Bhola, N. E., Angel, L. G. Z., Jansen, V. M., Estrada, M. M., Hutchinson, K. E., Giltnane, J. M., Schwarz, L. J., Lu, Y., Balko, J. M., Deas, O., Cairo, S., Judde, J. G., Mayer, I. A., Sanders, M., Dugger, T. C., Bianco, R., Stricker, T., & 1 othersArteaga, C. L., Feb 15 2019, In: Clinical Cancer Research. 25, 4, p. 1433 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  • Disclosure 100%
  • Estrogens 74%
  • Emotions 71%
  • Ligands 64%
  • Breast Neoplasms 57%

• Correction: Is there a future for Akt inhibitors in the treatment of cancer? (Clinical Cancer Research (2019) 22 (2599–2601) Doi:10.1158/1078-0432.CCR-16-0100)

  Jansen, V. M., Mayer, I. A. & Arteaga, C. L., Feb 15 2019, In: Clinical Cancer Research. 25, 4, p. 1436 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Disclosure 100%
  • Emotions 71%
  • Neoplasms 29%

• Erratum: Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer (eLife (2016) 5 PII: e44851)

  Joseph, J. D., Darimont, B., Zhou, W., Arrazate, A., Young, A., Ingalla, E., Walter, K., Blake, R. A., Nonomiya, J., Guan, Z., Kategaya, L., Govek, S. P., Lai, A. G., Kahraman, M., Brigham, D., Sensintaffar, J., Lu, N., Shao, G., Qian, J., Grillot, K., & 26 othersMoon, M., Prudente, R., Bischoff, E., Lee, K. J., Bonnefous, C., Douglas, K. L., Julien, J. D., Nagasawa, J. Y., Aparicio, A., Kaufman, J., Haley, B., Giltnane, J. M., Wertz, I. E., Lackner, M. R., Nannini, M. A., Sampath, D., Schwarz, L., Manning, H. C., Tantawy, M. N., Arteaga, C. L., Heyman, R. A., Rix, P. J., Friedman, L., Smith, N. D., Metcalfe, C. & Hager, J. H., Jan 7 2019, In: eLife. 8, e44851.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access
  4 Scopus citations

• Erratum: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (Annals of Oncology (2018) 29(7) (1541–1547), (S0923753419321052), (10.1093/annonc/mdy155))

  Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Petrakova, K., Blackwell, K. L., Winer, E. P., Janni, W., Verma, S., Conte, P., Arteaga, C. L., Cameron, D. A., Mondal, S., Su, F., Miller, M., Elmeliegy, M., Germa, C., & 1 othersO'Shaughnessy, J., Nov 2019, In: Annals of Oncology. 30, 11, p. 1842 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • ribociclib 100%
  • Letrozole 78%
  • Fees and Charges 70%
  • Disclosure 62%
  • Hormones 39%
  35 Scopus citations

• Erratum for the research article: Genomic proling of ER⁺ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance (Science Translational Medicine DOI: 10.1126/scitranslmed.aai7993)

  Giltnane, J. M., Hutchinson, K. E., Stricker, T. P., Formisano, L., Young, C. D., Estrada, M. V., Nixon, M. J., Du, L., Sanchez, V., Ericsson, P. G., Kuba, M. G., Sanders, M. E., Mu, X. J., Van Allen, E. M., Wagle, N., Mayer, I. A., Abramson, V., Gόmez, H., Rizzo, M., Toy, W., & 15 othersChandarlapaty, S., Mayer, E. L., Christiansen, J., Murphy, D., Fitzgerald, K., Wang, K., Ross, J. S., Miller, V. A., Stephens, P. J., Yelensky, R., Garraway, L., Shyr, Y., Meszoely, I., Balko, J. M. & Arteaga, C. L., Feb 13 2019, In: Science translational medicine. 11, 479, eaaw7620.

  Research output: Contribution to journal › Comment/debate › peer-review

  • Translational Medical Research 100%
  • Estrogens 72%
  • Breast Neoplasms 56%
  1 Scopus citations

• Erratum for The research article: The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation (Science Translational Medicine DOI: 10.1126/scitranslmed.aal4682)

  Kodack, D. P., Askoxylakis, V., Ferraro, G. B., Sheng, Q., Badeaux, M., Goel, S., Qi, X., Shankaraiah, R., Cao, Z. A., Ramjiawan, R. R., Bezwada, D., Patel, B., Song, Y., Costa, C., Naxerova, K., Wong, C. S. F., Kloepper, J., Das, R., Tam, A., Tanboon, J., & 13 othersDuda, D. G., Miller, C. R., Siegel, M. B., Anders, C. K., Sanders, M., Estrada, M. V., Schlegel, R., Arteaga, C. L., Brachtel, E., Huang, A., Fukumura, D., Engelman, J. A. & Jain, R. K., Jan 30 2019, In: Science translational medicine. 11, 477, aaw6935.

  Research output: Contribution to journal › Comment/debate › peer-review

  • Translational Medical Research 100%
  • Phosphatidylinositol 3-Kinases 87%
  • Breast Neoplasms 56%
  • Brain 43%

• Is Dual mTORC1 and mTORC2 Therapeutic Blockade Clinically Feasible in Cancer?

  Unni, N. & Arteaga, C. L., Nov 2019, In: JAMA Oncology. 5, 11, p. 1564-1565 2 p.

  Research output: Contribution to journal › Comment/debate › peer-review
  20 Scopus citations
• 2018

  Correction: Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer (Cancer Research (2017) 77 (2488-2499) DOI: 10.1158/0008-5472)

  Jansen, V. M., Bhola, N. E., Bauer, J. A., Formisano, L., Lee, K. M., Hutchinson, K. E., Witkiewicz, A. K., Moore, P. D., Estrada, M. V., Sánchez, V., Ericsson, P. G., Sanders, M. E., Pohlmann, P. R., Pishvaian, M. J., Riddle, D. A., Dugger, T. C., Wei, W., Knudsen, E. & Arteaga, C. L., Feb 15 2018, In: Cancer research. 79, 4, p. 874 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  • Disclosure 100%
  • RNA Interference 87%
  • Psychological Inhibition 74%
  • Emotions 71%
  • Breast Neoplasms 57%
  2 Scopus citations
• 2014

  Erratum: Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates (Proceedings of the National Academy of Sciences of the United States of America (2014) 111:11 (3955-3960) DOI:10.1073/pnas.1322937111)

  Yizhou, D., Kevin, T. L., Dorkin, J. R., Sasilada, S., Yunlong, Z., Delai, C., Roman, L. B., Hao, Y., Yi, C., Arturo, J. V., Christopher, A. A., Gaurav, S., Karsten, T. O., Weiheng, W., Avi, S., Abigail, K. R. L. J., Daniel, J. S., Akin, A., Carmen, B., Scott, A. B., & 10 othersMary, C., Kevin, F. F., Julia, H., Varun, K., Tatiana, I. N., June, Q., William, Q., Victor, K., Robert, L. & Daniel, G. A., Apr 15 2014, In: Proceedings of the National Academy of Sciences of the United States of America. 111, 15, p. 5753 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access
  1 Scopus citations
• 2013

  Mouse models and anti-HER2 therapies

  Hanker, A. B., Cook, R. S. & Arteaga, C. L., Nov 2013, In: Oncotarget. 4, 11, p. 1866-1867 2 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access
  4 Scopus citations
• 2011

  Dead-box or black-box: Is DDX1 a potential biomarker in breast cancer?

  Balko, J. M. & Arteaga, C. L., May 1 2011, In: Breast Cancer Research and Treatment. 127, 1, p. 65-67 3 p.

  Research output: Contribution to journal › Comment/debate › peer-review
  13 Scopus citations

• PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer: Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, et al (The Univ of Texas MD Anderson Cancer Ctr, Houston; Et al) Mol Cancer Ther 10:1093-1101, 2011

  Miller, T. W. & Arteaga, C. L., 2011, In: Breast Diseases. 22, 4, p. 367-370 4 p.

  Research output: Contribution to journal › Comment/debate › peer-review
• 2010

  Does lapatinib work against HER2-negative breast cancers?

  Mayer, I. A. & Arteaga, C. L., Mar 1 2010, In: Clinical Cancer Research. 16, 5, p. 1355-1357 3 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Lapatinib 100%
  • Estrogen Receptors 66%
  • Breast Neoplasms 45%
  • Estrogens 38%
  • Receptor Cross-Talk 38%
  15 Scopus citations
• 2009

  Inhibition of PI3K and MEK: It is all about combinations and biomarkers

  Rexer, B. N., Ghosh, R. & Arteaga, C. L., Jul 15 2009, In: Clinical Cancer Research. 15, 14, p. 4518-4520 3 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Mitogen-Activated Protein Kinase Kinases 100%
  • Phosphatidylinositol 3-Kinase 93%
  • Biomarkers 59%
  • PTEN Phosphohydrolase 43%
  • Breast Neoplasms 39%
  35 Scopus citations
• 2004

  Tyrosine kinase inhibitors: Why does the current process of clinical development not apply to them?

  Arteaga, C. L. & Baselga, J., Jun 2004, In: Cancer Cell. 5, 6, p. 525-531 7 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Protein-Tyrosine Kinases 100%
  • Gastrointestinal Stromal Tumors 65%
  • Trastuzumab 65%
  • Imatinib Mesylate 62%
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 57%
  87 Scopus citations
• 1998

  Erratum: Growth retardation and tumour inhibition by BRCA1 (Nature Genetics (1996) 12 (pp. 298-302))

  Holt, J. T., Thompson, M. E., Szabo, C., Robinson-Benion, C., Arteaga, C. L., King, M. C. & Jensen, R. A., 1998, In: Nature genetics. 19, 1, p. 102 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review
  5 Scopus citations
• 1997

  Erratum: Processing of the transforming growth factor β type I and II receptors. Biosynthesis and ligand-induced regulation (Journal of Biological Chemistry (1997) 272 (6423-6427))

  Koli, K. M. & Arteaga, C. L., 1997, In: Journal of Biological Chemistry. 272, 27, p. 17245 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review